Universität zu Köln

Mueller, Martin, Eastline, Jonathan, Nagler, Michael, Exadaktylos, Aristomenis K. and Sauter, Thomas C. (2019). Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists. Scand. J. Trauma Resusc. Emerg. Med., 27. LONDON: BMC. ISSN 1757-7241

Full text not available from this repository.

Abstract

BackgroundProthrombin complex concentrate (PCC) is widely used to reverse the action of direct oral anticoagulants (DOACs) in accordance with current guidelines and because of a lack of specific reversal agents. Indications, clinical characteristics and patient outcomes of patients might differ in comparison to reversal of vitamin K antagonists where reversal with PCC is well established.MethodsOur cohort study explores patient characteristics, indications and clinical outcomes for reversal of all DOAC patients receiving PCC at our university emergency department from 01.06.2012 to 01.07.2017, in comparison with patients on VKA.ResultsOut of 199,982 consultations, we studied 346 patients who were given PCC for reversal of either DOAC (n=74) or VKA (n=272). The most common reason for treatment was acute bleeding; in 86.7% of both groups. 37.3% of bleeding was traumatic (p=0.666). The most frequent bleeding location was intracranial (61.6%, p=0.881). Gastrointestinal bleeding was more often found in the DOAC group (18.9% vs. 8.8%, p=0.014). More erythrocyte concentrates (ECs) were given to DOAC patients with blood transfusion (p=0.014). Tranexamic acid was used more often in DOAC patients than in VKA patients (28.4% vs. 7.4%, p<0.001). No significant group differences were found for the following patient outcomes: in-hospital mortality, ICU stay, and length of stay at the ICU or in hospital.ConclusionIn DOAC treated patients, PCC was applied more often because of gastrointestinal bleeding and patients received higher numbers of ECs as well as tranexamic acid. No differences were observed with regard to important clinical outcomes.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Mueller, Martin UNSPECIFIED UNSPECIFIED UNSPECIFIED Eastline, Jonathan UNSPECIFIED UNSPECIFIED UNSPECIFIED Nagler, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Exadaktylos, Aristomenis K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Sauter, Thomas C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-150443
DOI:	10.1186/s13049-019-0625-3
Journal or Publication Title:	Scand. J. Trauma Resusc. Emerg. Med.
Volume:	27
Date:	2019
Publisher:	BMC
Place of Publication:	LONDON
ISSN:	1757-7241
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ACUTE CORONARY SYNDROMES; ANTIPLATELET THERAPY; DOUBLE-BLIND; RISK; MANAGEMENT; APIXABAN; EDOXABAN; PLACEBO Multiple languages Emergency Medicine Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15044